135 related articles for article (PubMed ID: 19356275)
1. Actual cost of providing long-acting reversible contraception: a study of Implanon cost.
Lipetz C; Phillips C; Fleming C
J Fam Plann Reprod Health Care; 2009 Apr; 35(2):75-9. PubMed ID: 19356275
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of a long-acting reversible contraceptive (Implanon) relative to oral contraception in a community setting.
Lipetz C; Phillips CJ; Fleming CF
Contraception; 2009 Apr; 79(4):304-9. PubMed ID: 19272500
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guideline.
Mavranezouli I;
Hum Reprod; 2008 Jun; 23(6):1338-45. PubMed ID: 18372257
[TBL] [Abstract][Full Text] [Related]
4. Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK.
Varney SJ; Guest JF
Pharmacoeconomics; 2004; 22(17):1141-51. PubMed ID: 15612832
[TBL] [Abstract][Full Text] [Related]
5. Addressing unmet need for long-acting family planning in Ethiopia: uptake of single-rod progestogen contraceptive implants (Implanon) and characteristics of users.
Asnake M; Henry EG; Tilahun Y; Oliveras E
Int J Gynaecol Obstet; 2013 Nov; 123 Suppl 1():e29-32. PubMed ID: 24035007
[TBL] [Abstract][Full Text] [Related]
6. Improving Contraceptive Access, Use, and Method Mix by Task Sharing Implanon Insertion to Frontline Health Workers: The Experience of the Integrated Family Health Program in Ethiopia.
Tilahun Y; Lew C; Belayihun B; Lulu Hagos K; Asnake M
Glob Health Sci Pract; 2017 Dec; 5(4):592-602. PubMed ID: 29229650
[TBL] [Abstract][Full Text] [Related]
7. Economic analysis of long-term reversible contraceptives. Focus on Implanon.
Phillips CJ
Pharmacoeconomics; 2000 Feb; 17(2):209-21. PubMed ID: 10947343
[TBL] [Abstract][Full Text] [Related]
8. What is the actual cost of providing the intrauterine system for contraception in a UK community sexual and reproductive health setting?
Cook L; Fleming C
J Fam Plann Reprod Health Care; 2014 Jan; 40(1):46-53. PubMed ID: 23625961
[TBL] [Abstract][Full Text] [Related]
9. The relationship between long-acting reversible contraception and insurance coverage: a retrospective analysis.
Broecker J; Jurich J; Fuchs R
Contraception; 2016 Mar; 93(3):266-72. PubMed ID: 26577755
[TBL] [Abstract][Full Text] [Related]
10. Continuation rates of Implanon in the UK: data from an observational study in a clinical setting.
Lakha F; Glasier AF
Contraception; 2006 Oct; 74(4):287-9. PubMed ID: 16982226
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Immediate Compared With Delayed Postpartum Etonogestrel Implant Insertion.
Gariepy AM; Duffy JY; Xu X
Obstet Gynecol; 2015 Jul; 126(1):47-55. PubMed ID: 26241255
[TBL] [Abstract][Full Text] [Related]
12. Real-world cost-effectiveness of etonogestrel implants compared to long-term and short term reversible contraceptive methods in France.
Linet T; Lévy-Bachelot L; Farge G; Crespi S; Yang JZ; Robert J; Fabron C
Eur J Contracept Reprod Health Care; 2021 Aug; 26(4):303-311. PubMed ID: 33960248
[TBL] [Abstract][Full Text] [Related]
13. Preventing repeat pregnancy in adolescents: is immediate postpartum insertion of the contraceptive implant cost effective?
Han L; Teal SB; Sheeder J; Tocce K
Am J Obstet Gynecol; 2014 Jul; 211(1):24.e1-7. PubMed ID: 24631431
[TBL] [Abstract][Full Text] [Related]
14. Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices.
Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists
Obstet Gynecol; 2012 Oct; 120(4):983-8. PubMed ID: 22996129
[TBL] [Abstract][Full Text] [Related]
15. Reasons for requesting removal of the hormonal implant, Implanon NXT, at an urban reproductive health clinic in KwaZulu-Natal, South Africa.
Beesham I; Smit J; Beksinska M; Panday M; Makatini V; Evans S
S Afr Med J; 2019 Sep; 109(10):750-755. PubMed ID: 31635572
[TBL] [Abstract][Full Text] [Related]
16. Evidence of patients' challenges and barriers related to usage of Implanon®: scoping review protocol.
Prosad S; Mashamba-Thompson TP; Ojewole E
Syst Rev; 2018 Oct; 7(1):157. PubMed ID: 30309380
[TBL] [Abstract][Full Text] [Related]
17. Feasibility and acceptability of using medical and nursing students to provide Implanon NXT at the community level in Kinshasa, Democratic Republic of Congo.
Hernandez JH; Akilimali P; Glover A; Bertrand JT
BMC Womens Health; 2020 Jun; 20(1):133. PubMed ID: 32580766
[TBL] [Abstract][Full Text] [Related]
18. Increasing LARC utilization: any woman, any place, any time.
Hathaway M; Torres L; Vollett-Krech J; Wohltjen H
Clin Obstet Gynecol; 2014 Dec; 57(4):718-30. PubMed ID: 25314089
[TBL] [Abstract][Full Text] [Related]
19. Neuropathy associated with etonogestrel implant insertion.
Brown M; Britton J
Contraception; 2012 Nov; 86(5):591-3. PubMed ID: 22770789
[TBL] [Abstract][Full Text] [Related]
20. The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience.
Graesslin O; Korver T
Eur J Contracept Reprod Health Care; 2008 Jun; 13 Suppl 1():4-12. PubMed ID: 18330813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
